An Open label prospective study of Sofosbuvir, Velpatasvir, voxilaprevir assessing efficacy and safety in the treatment of triple infection with Chronic Hepatitis C, Chronic Hepatitis B, and HIV
Latest Information Update: 12 Dec 2018
At a glance
- Drugs Sofosbuvir/velpatasvir/voxilaprevir (Primary)
- Indications Hepatitis B; Hepatitis C; HIV infections
- Focus Adverse reactions; Therapeutic Use
- Acronyms SOLVVE-C
Most Recent Events
- 13 Nov 2018 New trial profile.
- 13 Nov 2018 Results presented at The Liver Meeting 2018: 69th Annual Meeting of the American Association for the Study of Liver Diseases